1. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Issue 4 (5th May 2012) Authors: Burmester, Gerd R; Panaccione, Remo; Gordon, Kenneth B; McIlraith, Melissa J; Lacerda, Ana P M Journal: Annals of the rheumatic diseases Issue: Volume 72:Issue 4(2013) Page Start: 517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Issue 10273 (6th February 2021) Authors: Gordon, Kenneth B; Foley, Peter; Krueger, James G; Pinter, Andreas; Reich, Kristian; Vender, Ronald; Vanvoorden, Veerle; Madden, Cynthia; White, Katy; Cioffi, Christopher; Blauvelt, Andrew Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Issue 10273 (6th February 2021) Authors: Reich, Kristian; Papp, Kim A; Blauvelt, Andrew; Langley, Richard G; Armstrong, April; Warren, Richard B; Gordon, Kenneth B; Merola, Joseph F; Okubo, Yukari; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Vanvoorden, Veerle; Lebwohl, Mark Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Issue 10148 (25th August 2018) Authors: Gordon, Kenneth B; Strober, Bruce; Lebwohl, Mark; Augustin, Matthias; Blauvelt, Andrew; Poulin, Yves; Papp, Kim A; Sofen, Howard; Puig, Lluís; Foley, Peter; Ohtsuki, Mamitaro; Flack, Mary; Geng, Ziqian; Gu, Yihua; Valdes, Joaquin M; Thompson, Elizabeth H Z; Bachelez, Hervé Journal: Lancet Issue: Volume 392:Issue 10148(2018) Page Start: 650 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Rationale and early clinical data on IL-17 blockade in psoriasis. (July 2013) Authors: Nwe, Steven M; Champlain, Amanda H; Gordon, Kenneth B Journal: Expert review of clinical immunology Issue: Volume 9:Number 7(2013) Page Start: 677 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗